Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
NCT ID: NCT04281953
Last Updated: 2020-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2019-09-05
2020-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
From this, we can identify the specific needs of patients experiencing hearing loss and tinnitus following chemotherapy and develop a tailored and personalised support system.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Radiation Therapy Among Head and Neck Cancer Patients on the Inner Ear Function
NCT04214769
Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood
NCT06957132
Hearing Screening in Adults Over 50 Years Old
NCT06894927
Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Elderly Cancer Patients Within a Comprehensive Geriatric Assessment
NCT02381782
Association Between Severe-to-profound Hearing Loss and the Balance Function of the Inner Ear
NCT05500521
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There is a need to broaden research beyond the survival rates and address the need for support for those who are adapting to a life after cancer. Survivors are left with often permanent and possible life-debilitating effects from treatment. To date, there has been little research on the specific late effects of chemotherapy and the associated impact on quality of life.
Platinum-based chemotherapy, although highly effective, is known to cause ototoxicity, presenting often as permanent high frequency hearing loss and tinnitus. Hearing loss and tinnitus are associated with a higher risk of depression, social isolation and anxiety. The quality of social interactions for a person with hearing loss and tinnitus is diminished as taking part in conversations becomes challenging. This is particularly problematic as it means that the quality of life of these cancer survivors is reduced.
The impact hearing loss and tinnitus has on quality of life in cancer survivors remains unclear and under-studied. Because cancer therapies can potentially cause life-threatening side effects such as cardiotoxicity and nephrotoxicity, these become the priority. However, once these side acute effects subside, other long-term side effects remain and can permanently reduce quality of life. Cancer survivors may have already experienced a difficult journey from the diagnosis itself, the physical challenges of treatment and finally, remission. Re-adapting back to their previous life whilst in remission, but with added permanent side effects, both physically and psychologically, can be extremely difficult for some survivors.
Currently, there is little information and support offered to these patients who suffer from ototoxicity, potentially leading to many being undiagnosed and untreated. These patients can be affected by this toxicity for the rest of their lives, which can have a detrimental impact on their quality of life. It is essential that a deeper understanding and increased awareness of how hearing loss and tinnitus affects the quality of life of cancer survivors is sought to improve long-term symptoms management and support offered. This study aims to develop this and improve the support given to cancer survivors.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
People with ototoxicity
People living with and beyond who experience ototoxicity as a result of chemotherapy
High frequency audiometry
Simple hearing test
Short-Form 36-Item Questionnaire (SF-36)
Questionnaire on quality of life (Short Form 36 Item- SF-36)
Hearing handicap inventory for adults/elderly (HHIA/HHIE)
Questionnaire on Hearing loss (Hearing handicap inventory for adults/elderly- HHIA/HHIE)
Tinnitus handicap inventory (THI)
Questionnaire on Tinnitus (Tinnitus Handicap Inventory)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High frequency audiometry
Simple hearing test
Short-Form 36-Item Questionnaire (SF-36)
Questionnaire on quality of life (Short Form 36 Item- SF-36)
Hearing handicap inventory for adults/elderly (HHIA/HHIE)
Questionnaire on Hearing loss (Hearing handicap inventory for adults/elderly- HHIA/HHIE)
Tinnitus handicap inventory (THI)
Questionnaire on Tinnitus (Tinnitus Handicap Inventory)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has had at least 1 cycle- Was an adult (over 18) at the time of cancer diagnosis
Exclusion Criteria
* Radiotherapy to the head and neck area
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute for Health Research, United Kingdom
OTHER_GOV
International Stem Cell Forum
OTHER
University of Nottingham
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Baguley, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Nottingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Nottingham
Nottingham, Nottinghamshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18074
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.